Navigation Links
Early Study Finds Some Promise for Lung Cancer Vaccine
Date:4/4/2012

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, April 4 (HealthDay News) -- A new therapeutic vaccine appears to lengthen the lives of patients with a certain type of lung cancer, according to results of a small phase 2 trial.

The drug, belagenpumatucel-L (Lucanix), extended the lives of patients with nonprogressive non-small cell lung cancer and increased the five-year survival rate among some patients with moderately advanced cancer to 50 percent, researchers found.

For the study, 75 patients with stage 2, 3A, 3B or 4 cancer were randomly assigned to various doses of the vaccine, which was derived from four lung cancer cell lines. Staging refers to the severity of cancer. A stage 3 cancer has spread nearby, while a stage 4 cancer has spread to another organ.

Overall, the patients survived an average of 14.5 months and the five-year survival rate was 20 percent, lead researcher Dr. Lyudmila Bazhenova, an associate clinical professor at the University of California, San Diego Moores Cancer Center in La Jolla, and colleagues noted.

Patients with stage 3B and stage 4 disease who were given the two highest doses of the vaccine survived an average of 15.9 months. In these patients, average one-year survival rates were 61 percent, two-year survival rates averaged 41 percent and five-year survival rates were 18 percent.

But after chemotherapy, vaccinated patients with stage 3B or stage 4 nonprogressive cancer had an average survival of 44.4 months and five-year survival was 50 percent, which is "unheard of for patients with non-small cell lung cancer," Bazhenova said in a news release from the American Association for Cancer Research.

Patients whose disease progressed after chemotherapy survived an average of 14 months and had a 9 percent five-year survival rate, the researchers reported.

"This is a novel immunotherapy that appears to show unusually long survival in some patients," Bazhenova stated in the news release. The study authors also noted that a phase 3 clinical trial to confirm the results is currently under way in eight countries.

Commenting on the findings, Dr. Norman Edelman, chief medical officer of the American Lung Association, said: "This is a most interesting and potentially important study, as improving the survival rates of patients with relatively advanced lung cancer remains an important but difficult-to-achieve goal."

Vaccines to treat cancer have been around for a while with rather modest success so far, he said.

"While it is too early to call this study a breakthrough, it certainly is quite promising," added Edelman, who was not involved in the study.

A "randomized" trial -- one that randomly assigns patients to receive either the active vaccine or an inactive vaccine -- is needed to determine the real benefit of the therapy before it can be used to treat patients, however, Edelman noted.

"It is important to understand that this is prolongation of life and not a cure," Edelman said. "If the randomized trial confirms the findings, the approach will represent a significant contribution to the management of more advanced lung cancers."

The study findings were slated for presentation Wednesday at the American Association for Cancer Research annual meeting in Chicago.

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

For more about lung cancer, visit the U.S. National Cancer Institute.

SOURCES: Norman Edelman, M.D., chief medical officer, American Lung Association; April 4, 2012, presentation, American Association for Cancer Research annual meeting, Chicago


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. An Early Start for Your Child with Autism
2. New Stool Test Might Aid in Early Detection of Colon Cancer
3. Arteries under pressure early on
4. Early clinical data show galeterone safe, effective against prostate cancer
5. Warm Weather Triggers Early Allergy Season
6. Genetic causes found in nearly 1 in 5 patients with dilated cardiomyopathy heart failure
7. Research gives hope to detecting cancer in early stages
8. Nearly all states have taken action on Affordable Care Acts Patients Bill of Rights
9. Statin Alternative Looks Promising in Early Trials
10. Middle school teacher support lowers risk for early alcohol use
11. Dense breasts can nearly double the risk of breast cancer recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Early Study Finds Some Promise for Lung Cancer Vaccine
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may ... of groin injury, it occurs when the muscles around the pelvis become inflamed. ... around the lower torso, as well as accompanying tenderness and weakness. Without proper ...
(Date:3/27/2017)... Georgia (PRWEB) , ... March 27, 2017 , ... ... to announce that for a second year in a row; they are the ... healthcare designers in the industry voted on the award at Design Connections 2017. ...
(Date:3/27/2017)... ... ... The Anaheim Hills office accelerates and supports FNCC’s growth and further strengthens ... professionals over the past 6 months and is continuing to recruit new talent with ... of 2017. , “This new office is a direct result of our strong ...
(Date:3/27/2017)... ... March 27, 2017 , ... Golden Triangle Emergency Center will ... April 3rd to commemorate the two-year anniversary of the facility. The event will ... two great years while also familiarizing themselves with the facility. , In the ...
(Date:3/26/2017)... (PRWEB) , ... March 26, 2017 , ... ... worldwide to receive the RealSelf 100 Award, a prestigious award honoring the top ... procedures and to find and connect with doctors and clinics. , In 2016, ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 Cota ... for value-based precision medicine, today announced the ... Novartis Pharmaceuticals Corporation to help improve clinical ... As part of this agreement, ... collaboration entered into January 2016, teams from ...
(Date:3/24/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 ... of cell therapy manufacturing and focuses both on contract manufacturers ... are anticipated to emerge as viable alternatives to conventional treatment ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global Wound ... report to their offering. ... The global wound care market was worth $24,482.9 million in 2015 and ... Among the various wound care products type, the advanced wound ... 2015. Among the various applications, surgical wound segment held the largest share ...
Breaking Medicine Technology: